查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963831

癫痫药物市场－全球产业规模、份额、趋势、机会、预测：按药物、分销管道、地区和竞争格局划分，2021-2031年

Epilepsy Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drugs, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 186 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球癫痫治疗市场预计将从 2025 年的 71.6 亿美元成长到 2031 年的 85.9 亿美元，复合年增长率为 3.08%。

该产业涵盖抗惊厥药物和抗癫痫药物的研发和市场推广，旨在调节神经活动并控制神经性癫痫发作的频率。推动这一增长的关键因素包括全球慢性脑部疾病患病率的上升以及政府主导的诊断​​倡议的广泛实施。世界卫生组织（世卫组织）预测，到2024年，全球将有约5,000万人患有癫痫，凸显了对有效治疗性介入日益增长的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 71.6亿美元
市场规模：2031年 85.9亿美元
复合年增长率：2026-2031年 3.08%
成长最快的细分市场 第二代抗癫痫药物
最大的市场 北美洲

阻碍市场发展的主要障碍是发展中国家医疗基础设施不足，导致治疗资源严重匮乏。这种差距限制了患者获得基本药物的机会，也阻碍了製药公司在新兴经济体的商业性扩张。世界卫生组织的数据显示，到2024年，低收入国家约75%的癫痫患者将无法获得必要的医疗服务，这将严重阻碍抗癫痫药物的公平分配。

市场驱动因素

全球癫痫和癫痫发作性疾病发生率的上升是市场扩张的主要驱动力，导致需要长期药物治疗的患者人数不断增加。由于遗传因素和后天性脑损伤导致盛行率上升，所有患者群体对有效抗癫痫药物的需求日益增长。为了满足不断扩大的患者群体，需要提高基本药物的产能并建立永续的供应链。正如美国疾病管制与预防中心 (CDC) 于 2024 年 5 月发布的最新版《癫痫基础知识》中所述，美国约有 300 万成年人患有活动性癫痫，凸显了对癫痫控制干预措施的巨大需求。这对製造商至关重要，因为他们需要确保稳定的商业性基础，以扩展其治疗产品组合。

同时，第三代抗癫痫药物的进步正在提升市场价值，满足了难治性癫痫治疗领域尚未充分满足的重大需求。这些新型製剂具有精准的作用机制，可针对特定综合征，为对标准治疗无效的患者提供了可行的选择。这些特效疗法的商业性成功凸显了市场正从学名药转向高价值疗法。例如，Jazz Pharmaceuticals在2024年11月发布的2024年第三季财报中披露，其Epidiolex净销售额成长18%，达到2.516亿美元。同样，UCB在2024年7月发布的2024年第一季财报中宣布，其Fintepla上半年净销售额达到1.54亿欧元。这反映了由针对复杂神经系统疾病的创新药物所驱动的强劲成长势头。

市场挑战

发展中地区治疗选择上的严重差异以及医疗基础设施的不足，是限制全球癫痫治疗市场发展的主要阻碍因素。这种结构性缺陷直接限制了製药公司的商业性潜力，从物理和经济层面阻碍了抗癫痫药物向全球绝大多数患者的流通。由于缺乏健全的诊断网络和可靠的供应链，数百万潜在患者仍未得到诊断或无法获得持续的处方笺，这大大缩小了可有效开拓的市场。难以打入高发新兴市场导致收入停滞不前，迫使企业过度依赖已饱和的已开发经济体。

近期药物供应数据凸显了这项限制的严重性。根据国际癫痫联盟统计，截至2023年，全球仅有五分之一的癫痫患者能够获得价格合理的抗癫痫药物。这项数据表明，儘管癫痫病发病率很高，但该行业的实际商业性覆盖范围实际上仅占总需求的一小部分。因此，这种差距对市场估值和扩张设定了明确的上限，直接限制了该行业的财务表现。

市场趋势

数位健康和​​穿戴式监测技术的融合正在重塑患者照护的基础，将治疗重点从被动应对转向预防和全面管理。这一趋势包括引入人工智慧驱动的平台和智慧型设备，这些平台和设备能够持续追踪癫痫发作活动，并透过实现患者和神经科之间的即时数据共用来优化治疗效果。製药公司正积极利用这种协同效应，建立专门负责数位疗法的商业部门，从而拓展其价值提案，使其超越传统药物的范畴。例如，SK Biopharmaceuticals 于 2025 年 10 月与 Europharma 成立了一家合资企业 Mentiscare，旨在将基于人工智慧的癫痫管理平台商业化，该平台提供癫痫发作检测和个人化护理解决方案。

同时，为了帮助那些对现有标准疗法无效的患者，抗药性癫痫治疗药物的研发工作也正在加速。製药公司正大力投资其临床研发管线，开发具有独特作用机制的新型小分子候选药物，例如钾通道开放剂，以治疗局部癫痫发作和其他难治性癫痫。这项策略性倡议得到了大量资金的支持，用于开展旨在将下一代疗法推向市场的后期临床试验。根据氙气 Pharmaceuticals公司于2025年2月发布的《2024年第四季及全年财务表现报告》，该公司报告其现金及投资头寸为7.544亿美元，主要用于支持其抗癫痫药物azetucalnar的III期临床试验项目。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球癫痫药物市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物分类（第一代抗癫痫药物、第二代抗癫痫药物、第三代抗癫痫药物）
    • 分销通路（医院药局、零售药局、网路药局、其他）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美癫痫药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲癫痫药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区癫痫药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲癫痫药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美癫痫药物市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球癫痫药物市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Novartis AG
  • GlaxoSmithKline plc
  • Sanofi S.Aa
  • UCB SA
  • Abbott Laboratories
  • Bausch Health Companies, Inc
  • Viatris Inc.
  • Johnson & Johnson
  • Sumitomo Pharma Co., Ltd
  • H. Lundbeck A/S

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 20617

The Global Epilepsy Drugs Market is projected to expand from USD 7.16 Billion in 2025 to USD 8.59 Billion by 2031, reflecting a CAGR of 3.08%. This industry sector encompasses the development and sale of anticonvulsant medications and antiseizure therapies intended to regulate neuronal activity and manage the frequency of neurological episodes. Key drivers fueling this growth include the increasing global prevalence of chronic brain disorders and the broader implementation of government-led diagnostic initiatives. According to the World Health Organization, approximately 50 million people worldwide were living with epilepsy in 2024, underscoring the critical and growing demand for effective therapeutic interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 7.16 Billion
Market Size 2031USD 8.59 Billion
CAGR 2026-20313.08%
Fastest Growing SegmentSecond Generation Anti Epileptics
Largest MarketNorth America

A major hurdle hindering market progress is the significant treatment gap existing in developing regions where healthcare infrastructure remains inadequate. This disparity limits patient access to essential medicines and curtails the commercial reach of pharmaceutical manufacturers in emerging economies. Data from the World Health Organization indicates that in 2024, nearly 75% of individuals with epilepsy in low-income countries did not receive necessary medical treatment, representing a substantial barrier to the equitable distribution of antiseizure products.

Market Driver

The increasing global incidence of epilepsy and seizure disorders serves as a primary catalyst for market expansion, elevating the volume of patients requiring long-term pharmacological management. As prevalence grows due to genetic factors and acquired brain injuries, the demand for effective anticonvulsant therapies is intensifying across all patient demographics. This expanding patient pool necessitates higher production capacities and sustained supply chains for essential medications. As noted by the Centers for Disease Control and Prevention in their May 2024 'Epilepsy Basics' update, roughly 3 million adults in the United States reported having active epilepsy, highlighting the substantial demand for seizure control interventions and ensuring a stable commercial foundation for manufacturers to scale their therapeutic portfolios.

Simultaneously, advancements in third-generation anti-epileptic drug formulations are boosting market value by addressing critical unmet needs in treatment-resistant epilepsy. These novel formulations offer precision mechanisms to target specific syndromes, providing effective options for patients unresponsive to standard care. The commercial success of these specialized therapies highlights the market's shift towards high-value treatments over generic alternatives. For instance, Jazz Pharmaceuticals reported in its 'Third Quarter 2024 Financial Results' in November 2024 that net product sales for Epidiolex increased by 18% to $251.6 million. Similarly, UCB announced in its 'Half-Year Report 2024' in July 2024 that net sales for Fintepla reached €154 million in the first six months, reflecting the robust trajectory driven by innovative drugs tailored to complex neurological profiles.

Market Challenge

The profound treatment gap and insufficient healthcare infrastructure in developing regions function as severe restraints on the Global Epilepsy Drugs Market. This structural deficiency directly curtails the commercial potential of pharmaceutical manufacturers by physically and economically preventing the distribution of anticonvulsant therapies to a majority of the global patient population. Without robust diagnostic networks and reliable supply chains, the effective addressable market shrinks significantly, as millions of potential consumers remain undiagnosed or unable to obtain consistent prescriptions. This inability to penetrate high-prevalence emerging markets stagnates revenue volume and forces companies to rely disproportionately on saturated developed economies.

The magnitude of this restriction is evident in recent data regarding medication accessibility. According to the International League Against Epilepsy, in 2023, only one in five people with epilepsy globally had access to affordable anti-seizure medicines. This statistic indicates that despite the high prevalence of the condition, the actual commercial reach of the industry is effectively capped at a fraction of total demand. Consequently, this disparity creates a tangible ceiling for market valuation and expansion, directly limiting the financial performance of the sector.

Market Trends

The integration of digital health and wearable monitoring technologies is fundamentally reshaping patient care by shifting focus from reactive treatment to proactive, holistic management. This trend involves the deployment of AI-driven platforms and smart devices that continuously track seizure activity, enabling real-time data sharing between patients and neurologists to optimize therapeutic outcomes. Pharmaceutical companies are increasingly capitalizing on this synergy by establishing commercial entities dedicated to digital therapeutics, thereby extending their value proposition beyond traditional medication. For instance, in October 2025, SK Biopharmaceuticals established a joint venture named Mentis Care with Eurofarma to commercialize an artificial intelligence-based epilepsy management platform aimed at providing seizure detection and personalized care solutions.

Simultaneously, there is an intensified R&D focus on drug-resistant epilepsy therapies, driven by the need to support patients who do not respond to existing standard-of-care medications. Manufacturers are heavily investing in clinical pipelines to develop novel small molecule candidates with unique mechanisms of action, such as potassium channel openers, to address focal onset seizures and other refractory conditions. This strategic commitment is evidenced by substantial capital allocation toward late-stage clinical trials intended to bring these next-generation treatments to market. According to Xenon Pharmaceuticals, in its 'Fourth Quarter and Full Year 2024 Financial Results' released in February 2025, the company reported a cash and investment position of $754.4 million to largely support the advancement of its Phase 3 epilepsy program for azetukalner.

Key Market Players

  • Novartis AG
  • GlaxoSmithKline plc
  • Sanofi S.Aa
  • UCB S.A.
  • Abbott Laboratories
  • Bausch Health Companies, Inc
  • Viatris Inc.
  • Johnson & Johnson
  • Sumitomo Pharma Co., Ltd
  • H. Lundbeck A/S

Report Scope

In this report, the Global Epilepsy Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Epilepsy Drugs Market, By Drugs

  • First Generation Anti-epileptics
  • Second Generation Anti-epileptics
  • Third Generation Anti-epileptics

Epilepsy Drugs Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Epilepsy Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Epilepsy Drugs Market.

Available Customizations:

Global Epilepsy Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Epilepsy Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drugs (First Generation Anti-epileptics, Second Generation Anti-epileptics, Third Generation Anti-epileptics)
    • 5.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Epilepsy Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drugs
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Epilepsy Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drugs
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Epilepsy Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drugs
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Epilepsy Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drugs
        • 6.3.3.2.2. By Distribution Channel

7. Europe Epilepsy Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drugs
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Epilepsy Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drugs
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Epilepsy Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drugs
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Epilepsy Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drugs
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Epilepsy Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drugs
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Epilepsy Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drugs
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Epilepsy Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drugs
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Epilepsy Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drugs
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Epilepsy Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drugs
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Epilepsy Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drugs
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Epilepsy Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drugs
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Epilepsy Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drugs
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Epilepsy Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drugs
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Epilepsy Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drugs
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Epilepsy Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drugs
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Epilepsy Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drugs
        • 9.3.3.2.2. By Distribution Channel

10. South America Epilepsy Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drugs
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Epilepsy Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drugs
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Epilepsy Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drugs
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Epilepsy Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drugs
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Epilepsy Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Novartis AG
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. GlaxoSmithKline plc
  • 15.3. Sanofi S.Aa
  • 15.4. UCB S.A.
  • 15.5. Abbott Laboratories
  • 15.6. Bausch Health Companies, Inc
  • 15.7. Viatris Inc.
  • 15.8. Johnson & Johnson
  • 15.9. Sumitomo Pharma Co., Ltd
  • 15.10. H. Lundbeck A/S

16. Strategic Recommendations

17. About Us & Disclaimer